Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01752023 · ClinicalTrials.gov registry record · Phase 2
A Randomized Phase II Study of SUBATM-itraconazole in Patients With Untreated Squamous NSCLC.
A Phase 2 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT01752023 is a Phase 2 study that was terminated before completion, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 3 participants.
The verdict
NCT01752023, a Phase 2 study, was terminated before completion, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
Response rates. Changes in tumor blood flow.
Interventions
- DRUG Cisplatin + Gemcitabine
- DRUG Cisplatin + Gemcitabine with SUBATM-itraconazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2013-03 |
| Est. Completion | 2014-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01752023
The ClinicalTrials.gov registry entry for NCT01752023 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cisplatin + Gemcitabine is the first listed.
NCT01752023 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01752023 about?
NCT01752023 is a clinical study titled "A Randomized Phase II Study of SUBATM-itraconazole in Patients With Untreated Squamous NSCLC.". Response rates. Changes in tumor blood flow.
What is the current status of trial NCT01752023?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2013-03. Estimated completion is 2014-04.
What interventions are being tested in trial NCT01752023?
The interventions under investigation include: Cisplatin + Gemcitabine (DRUG), Cisplatin + Gemcitabine with SUBATM-itraconazole (DRUG).
Who is sponsoring clinical trial NCT01752023?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.